title: Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation.
abstract: We describe a patient with probable dementia with Lewy bodies (DLB) whose Parkinsonism worsened after administration of rivastigmine within the therapeutic dose range. Some extrapyramidal signs (EPS) then reversed to pre-treatment level after rivastigmine dose reduction. We draw attention to the need of EPS monitoring during titration of cholinesterase inhibitors in patients with DLB. This is the first report to our knowledge of iatrogenic worsening of Parkinsonism which was successfully managed by dose reduction.
authors.affiliation: Centre for Research and Treatment on Cognitive Dysfunctions, Institute of Clinical Neurology, Department of Clinical Sciences, Luigi Sacco Hospital, University of Milan, Via G.B. Grassi 74, I-20157, Milan, Italy. francesca.clerici1@unimi.it
authors.forename: F
authors.initials: F
authors.lastname: Clerici
authors.forename: P L
authors.initials: PL
authors.lastname: Ratti
authors.forename: S
authors.initials: S
authors.lastname: Pomati
authors.forename: L
authors.initials: L
authors.lastname: Maggiore
authors.forename: A
authors.initials: A
authors.lastname: Elia
authors.forename: C
authors.initials: C
authors.lastname: Mariani
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000368:Aged; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D006801:Humans; D020961:Lewy Body Disease / Q000150:complications; D008297:Male; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000209:etiology; D048448:Phenylcarbamates / Q000008:administration & dosage* / Q000009:adverse effects; D000068836:Rivastigmine; D013997:Time Factors
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000109:Acetylcholine; D000068836:Rivastigmine